HER-2 Positive Breast Cancer Clinical Trial
Official title:
Observational, Cross-sectional Study to Analyze the Characteristics of Disseminated Her2+ Breast Cancer Patients Treated With Trastuzumab That Have Reached Complete Remission, Partial Remission or Stabilization of Disease During More Than 3 Years
Main objective: To analyze the clinical and biological characteristics of patients with
disseminated breast cancer HER2 + treated with trastuzumab that have achieved a complete
remission, partial or stable disease for a period exceeding 3 years.
In addition, there will be a sub-genetic analysis of patients in whom there is availability
a sample of primary tumor preserved in paraffin. This sub-analysis will not interfere with
routine clinical practice, as the tumor samples based on which will be held on genetic
profile, have been preserved in paraffin was extracted from the primary tumor to the
patient.
SECONDARY OBJECTIVES:
- To determine the frequency of patients achieving partial response or stable disease for
a period exceeding 3 years.
- Know the time to complete or partial remission or to achieve stabilization of the
disease.
- Know the length of the complete or partial remission or time to disease stabilization
of patients.
- Knowing the pattern of treatment that has achieved complete or partial remission or
stabilization of disease and duration.
- Knowledge of overall survival.
- Knowing the toxicity of prolonged administration of trastuzumab.
- Identify the primary tumor genes HER-2 associated with such prolonged responses.
The source document will be in all cases the clinical history and in the case of patients
selected for the sub-genetic analysis, the report resulting from it.
The study is carried out by filling a notebook of electronic data collection that gathers
all available information contained in medical records.
The sub-genetic analysis will be performed at the Hospital de la Paz. Both, the processing
of samples and conducting the analysis using qRT-PCR, will be performed in this hospital.
All data are stored, ensuring the confidentiality, security and authenticity .The forms must
be reviewed by the monitor.
Once recorded the data, the database will be revised and monitored to submit those records
in which there are inconsistencies or missing information . Following the closure of the
database will be a report which will present the results of the analysis of the data.
;
Observational Model: Case-Only, Time Perspective: Cross-Sectional
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01432223 -
Primary Chemotherapy With Anthracycline Followed by Nab-paclitaxel and Trastuzumab
|
Phase 2 | |
Completed |
NCT01305941 -
A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases
|
Phase 2 | |
Recruiting |
NCT05871918 -
A Multicenter, Randomized, Open, Phase III Trial of ddEC-THPvs Evaluating the Efficacy and Safety of TCHP Neoadjuvant Therapy for HER2-positive Breast Cancer
|
Phase 3 | |
Terminated |
NCT02598310 -
Neoadjuvant Nab-PTX and Trastuzumab for ER Negative and HER2 Positive Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT02568839 -
Neoadjuvant Response-guided Treatment of HER2 Positive Breast Cancer
|
Phase 2/Phase 3 | |
Completed |
NCT02675231 -
A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT02154529 -
Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT01565200 -
HER2 Imaging Study to Identify HER2 Positive Metastatic Breast Cancer Patient Unlikely to Benefit From T-DM1
|
Phase 2 | |
Completed |
NCT01340430 -
Neoadjuvant 5-fluorouracil, Epirubicin and Cyclophosphamide (FEC) Followed by Weekly Paclitaxel and Trastuzumab in Her2 Positive Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT02947685 -
Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer
|
Phase 3 | |
Completed |
NCT02066532 -
Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01583426 -
Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto)
|
Phase 3 | |
Completed |
NCT01677455 -
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
|
Phase 2 | |
Withdrawn |
NCT01361945 -
AUY922 With Lapatinib and Letrozole for ER+ HER2+ Advanced Breast Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02326974 -
T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA
|
Phase 2 | |
Not yet recruiting |
NCT04644406 -
PETRA: PErtuzumab and Trastuzumab Biosimilars Real Life Association for the First Line Treatment of HER2-positive Metastatic Breast Cancer, an Observational Prospective Multicenter Study
|
||
Terminated |
NCT02131506 -
A Study of Lapatinib in Combination With Caelyx in Patients With Advanced HER2 Positive Pretreated Breast Cancer
|
Phase 1 | |
Completed |
NCT00788931 -
A Trial l of Panobinostat Given in Combination With Trastuzumab and Paclitaxel in Adult Female Patients With HER2 Positive Metastatic Breast Cancer
|
Phase 1 | |
Completed |
NCT02488564 -
A Study of Liposomal Doxorubicin + Docetaxel + Trastuzumab + Metformin in Operable and Locally Advanced HER2 Positive Breast Cancer
|
Phase 2 | |
Completed |
NCT02492711 -
Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer
|
Phase 3 |